Over-treatment of carbapenemase-producing Enterobacteriaceae

Scandinavian Journal of Infectious Diseases

Volumn 44, Issue 5, 2012, Pages 325-329

  Rihani, Deba S ^a   Wallace, Mark R ^b   Sieger, Barry E ^b   Waite, Robert A ^a   Fox, Marlena ^a   Brown, Scott A ^b   Deryke, C Andrew ^a  

^a ORLANDO REGIONAL MEDICAL CENTER   (United States)

^b ORLANDO HEALTH   (United States)

Author keywords

Carbapenem resistant Enterobacteriaceae (CRE); Colonization; Enterobacteriaceae; Klebsiella pneumoniae carbapenemase (KPC); Modified Hodge test

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEMASE; CEFEPIME; CIPROFLOXACIN; COLISTIN; IMIPENEM; MEROPENEM; RIFAMPICIN; TIGECYCLINE; TOBRAMYCIN;

ABSCESS; ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; CLINICAL ARTICLE; COHORT ANALYSIS; DEBRIDEMENT; DECUBITUS; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LUNG INFECTION; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PNEUMONIA; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SCORING SYSTEM; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; COLISTIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; THIENAMYCINS; TREATMENT OUTCOME;

EID: 84859763019     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.638318     Document Type: Article

References (18)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert t D, Rice LB, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
2. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program (2000 - 2004). Microb Drug Resist 2006;12:223-30.
3. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228-36.
4. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): An emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010;65:1119-25.
5. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase-and metallo-beta-lactamase-producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008;52:570-3.
6. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: Molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005;56:128-32.
7. DeRyke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010;54:4503-5.
8. US Food and Drug Administration Safety Communication. Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections, 09-01-2010. Available at: http://www.fda.gov/Drugs/ DrugSafety/ucm224370.htm (accessed 6 October 2010).
9. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-106.
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 20th informational supplement. CLSI document M100-S20.Wayne, PA: CLSI; 2010.
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classifi cation system. Crit Care Med 1985;13:818-29.
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; update. CLSI document M100-S20, June 2010 update. Wayne, PA: CLSI; 2010.
13. Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2008;62:1311-8.
14. Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG. Decreased susceptibility to polymyxin B during treatment for carbapenemresistant Klebsiella pneumoniae infection. J Clin Microbiol 2009;47:1611-2.
15. Pournaras S, Kristo I, Vrioni G, Ikonomidis A, Poulou A, Petropoulou D, et al. Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae. J Clin Microbiol 2010;48:2601-4.
16. Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn Microbiol Infect Dis 2009;64:233-5.
17. Anderson KF, Lonsway DR, Rasheed JK, Biddle J, Jensen B, McDougal LK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007;45:2723-5.
18. Woodford N, Dallow JW, Hill RL, Palepou MF, Pike R, Ward ME, et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int. J. Antimicrob Agents 2007;24:456-9.